Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge

English version České info

Inactivated poliovirus vaccine (IPV) may be used in mass vaccination campaigns during the final stages of polio eradication. It is also likely to be adopted by many countries following the coordinated global cessation of vaccination with oral poliovirus vaccine (OPV) after eradication. The success of IPV in the control of poliomyelitis outbreaks will depend on the degree of nasopharyngeal and intestinal mucosal immunity induced against poliovirus infection. We performed a systematic review of studies published through May 2011 that recorded the prevalence of poliovirus shedding in stool samples or nasopharyngeal secretions collected 5–30 days after a “challenge” dose of OPV. Studies were combined in a meta-analysis of the odds of shedding among children vaccinated according to IPV, OPV, and combination schedules. We identified 31 studies of shedding in stool and four in nasopharyngeal samples that met the inclusion criteria. Individuals vaccinated with OPV were protected against infection and shedding of poliovirus in stool samples collected after challenge compared with unvaccinated individuals (summary odds ratio [OR] for shedding 0.13 (95% confidence interval [CI] 0.08–0.24)). In contrast, IPV provided no protection against shedding compared with unvaccinated individuals (summary OR 0.81 [95% CI 0.59–1.11]) or when given in addition to OPV, compared with individuals given OPV alone (summary OR 1.14 [95% CI 0.82–1.58]). There were insufficient studies of nasopharyngeal shedding to draw a conclusion. IPV does not induce sufficient intestinal mucosal immunity to reduce the prevalence of fecal poliovirus shedding after challenge, although there was some evidence that it can reduce the quantity of virus shed. The impact of IPV on poliovirus transmission in countries where fecal-oral spread is common is unknown but is likely to be limited compared with OPV.

Vyšlo v časopise: Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge. PLoS Pathog 8(4): e32767. doi:10.1371/journal.ppat.1002599
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002599

Souhrn

Zdroje

1. HinmanARFoegeWHDequadrosCAPatriarcaPAOrensteinWA 1987 The case for global eradication of poliomyelitis. Bull WHO 65 835 840

2. GhendonYRobertsonSE 1994 Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull WHO 72 973 983

3. OgraPLKarzonDTRighthandFMacGillivrayM 1968 Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med 279 893 900

4. ValtanenSRoivainenMPiirainenLStenvikMHoviT 2000 Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J Infect Dis 182 1 5

5. HenryJLJaikaranESDaviesJRTomlinsonAJMasonPJ 1966 A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond) 64 105 120

6. KriegCMaierRMeyerhansA 2004 Gut-homing (alpha(4)beta(+)(7)) Th1 memory responses after inactivated poliovirus immunization in poliovirus orally pre-immunized donors. J Gen Virol 85 1571 1579

7. HerremansTMReimerinkJHBuismanAMKimmanTGKoopmansMP 1999 Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162 5011 5018

8. World Health Organization 2006 Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 81 137 144

9. ResikSTejedaALagoPMDiazMCarmenatesA 2010 Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 201 1344 1352

10. MohammedAJAlAwaidySBawikarSKurupPJElamirE 2010 Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 362 2351 2359

11. Oliver Wyman Inc 2009 Global post-eradication IPV supply and demand assessment: integrated findings. Commissioned by the Bill & Melinda Gates Foundation. Available: http://www.polioeradication.org/Research/AffordableIPV.aspx. Accessed 21 March 2012

12. EhrenfeldEGlassRIAgolVIChumakovKDowdleW 2008 Immunisation against poliomyelitis: moving forward. Lancet 371 1385 1387

13. JohnTJ 1993 Immunisation against polioviruses in developing countries. Rev Med Virol 3 149 160

14. AlexanderJPJrGaryHEJrPallanschMA 1997 Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 175 suppl. 1 S176 S182

15. SutterRWPatriarcaPA 1993 Inactivated and live, attenuated poliovirus vaccines: mucosal immunity. KurstakE Measles and poliomyelitis Springer-Verlag

16. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine 1995 Factors affecting the immunogenicity of oral poliovirus vaccine - a prospective evaluation in Brazil and the Gambia. J Infect Dis 171 1097 1106

17. GhendonYZSanakoyevaII 1961 Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol 5 265 273

18. GalindoMLagoPMCaceresVLandaverdeMSutterR (Cuba IPV Study Collaborative Group) 2007 Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. New Engl J Med 356 1536 1544

19. LaassriMLottenbachKBelsheRWolffMRennelsM 2005 Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 192 2092 2098

20. Enders-RuckleGSiegertR 1961 [Viral excretion and antibody formation after use of a live trivalent poliomyelitis vaccine (Cox-Lederle)]. Dtsch Med Wochenschr 86 1999 2008

21. MarineWMChinTDYGravelleCR 1962 Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg 76 173 195

22. WehrlePFReichertRCarbonaroOPortnoyB 1958 Influence of prior active immunization on the presence of poliomyelitis virus in the pharynx and stools of family contacts of patients with paralytic poliomyelitis. Pediatrics 21 353 361

23. WehrlePFCarbonaroODayPAWhalenJPReichertR 1961 Transmission of polioviruses. III. Prevalence of polioviruses in pharyngeal secretions of infected household contacts of patients with clinical disease. Pediatrics 27 762 764

24. DavisDCLipsonMJCarverDHMelnickJLRobbinsFC 1958 The degree and duration of poliomyelitis virus excretion among vaccinated household contacts of clinical cases of poliomyelitis. Pediatrics 22 33 40

25. DowdleWVan der AvoortHde GourvilleEDelpeyrouxFDesphandeJ 2006 Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Analysis 26 1449 1469

26. World Health Organization 2008 Polio eradication: surveys of routine immunization coverage and seroprevalence against polioviruses, Yogyakarta Province, Indonesia. Wkly Epidemiol Rec 83 45 48

27. TroySBFerreyra-ReyesLHuangCHMahmudNLeeYJ 2011 Use of a novel real-time PCR assay to detect oral polio vaccine shedding and reversion in stool and sewage samples after a Mexican national immunization day. J Clin Microbiol 49 1777 1783

28. MurdinADBarretoLPlotkinS 1996 Inactivated poliovirus vaccine: past and present experience. Vaccine 14 735 746

29. BijkerkH 1979 Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand 43 195 206

30. van der AvoortHGAReimerinkJHJRasAMuldersMNvan LoonAM 1995 Isolation of epidemic poliovirus from sewage during the 1992-3 type-3 outbreak in the Netherlands. Epidemiol Infect 114 481 491

31. HoviTCantellKHuovilainenAKinnunenEKuronenT 1986 Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1 1427 1432

32. BottigerMMellinPRomanusVSoderstromHWesslenT 1979 Epidemiological events surrounding a paralytic case of poliomyelitis in Sweden. Bull WHO 57 99 103

33. SlaterPEOrensteinWAMoragAAvniAHandsherR 1990 Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 335 1192 1198

34. OostvogelPMRumkeHCConyn-van SpaendonckMAEvan der AvoortHLeeuwenburgJ 2001 Poliovirus circulation among schoolchildren during the early phase of the 1992–1993 poliomyelitis outbreak in The Netherlands. J Infect Dis 184 1451 1455

35. PatriarcaPAWrightPFJohnTJ 1991 Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev Infect Dis 13 926 939

36. NathansonN 2008 The pathogenesis of poliomyelitis: What we don't know. MaramoroschKShatkinAJMurphyFA Advances in virus research. Volume 71 San Diego Elsevier Academic Press Inc 1 50

37. WahidRCannonMJChowM 2005 Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol 79 5988 5995

38. GrasslyNCJafariHBahlSSethiRDeshpandeJM 2012 Waning intestinal immunity following vaccination with oral poliovirus vaccines in India. J Infect Dis In press

39. GrasslyNCJafariHBahlSDurraniSWengerJ 2010 Asymptomatic wild poliovirus infection in India among children previously immunized with oral poliovirus vaccine. J Infect Dis 201 1535 1543

40. World Health Organization 2010 Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 85 213 228

41. KrugmanSWarrenJEigerMSBermanPHMichaelsRM 1961 Immunization with live attenuated poliovirus vaccine. Am J Dis Child 101 23 29

42. SutterRWSuleimanAJMMalankarPAl-KhusaibySMehtaF 2000 Trial of a supplemental dose of four poliovirus vaccines. New Engl J Med 343 767 773

43. HigginsJPTGreenS 2011 Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. Available: http://www.cochrane-handbook.org. Accessed 21 March 2012

44. DersimonianRLairdN 1986 Meta-analysis in clinical trials. Control Clin Trials 7 177 188

45. R Development Core Team 2010 R: a language and environment for statistical computing Vienna, Austria R Foundation for Statistical Computing ISBN: 3-900051-07-0

46. MoherDLiberatiATetzlaffJAltmanDGThePG 2009 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6 e1000097 doi:10.1371/journal.pmed.1000097

47. ModlinJFHalseyNAThomsMLMeschievitzCKPatriarcaPA 1997 Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine - Live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 175 S228 S234

48. du ChateletIPMerchantATFisher-HochSLubySPPlotkinSA 2003 Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 21 1710 1718

49. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines 1997 Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. J Infect Dis 175 suppl. 1 S215 S227